Amicus Therapeutics

Michael J. Fox Foundation unites industry groups for research tool development

Friday, September 13, 2013

The Michael J. Fox Foundation for Parkinson’s research (MJFF) has launched the Parkinson’s Disease Research Tools Consortium. MJFF and seven industry partners have organized to grow the Foundation’s ongoing efforts to better understand existing tools—such as preclinical models, antibodies and cell lines—and their use in laboratory experiments, as well as to develop new tools to address unmet challenges.

[Read More]

Amicus Therapeutics, Biogen Idec collaborate for Parkinson’s disease

Wednesday, September 11, 2013

Amicus Therapeutics, a biopharmaceutical company developing therapies for rare and orphan diseases, is collaborating with Biogen Idec to discover, develop and commercialize novel small molecules for the treatment of Parkinson’s disease. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson’s.

[Read More]

Amicus to relaunch phase II

Wednesday, March 9, 2011

Amicus Therapeutics is planning a new phase II study of its experimental therapy for Pompe disease, AT2220, now that the FDA has decided to lift a clinical hold on the program. The Cranbury, N.J.-based biotech says it expects to have phase II data available before the end of 2011.

[Read More]